Annals of Surgical Oncology, Vol 2, Issue 1 26-31, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Primary gastrointestinal sarcomas: analysis of prognostic variables

K. C. Conlon, E. S. Casper and M. F. Brennan
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.

BACKGROUND: Primary gastrointestinal sarcomas are uncommon, and the clinicopathological determinants of survival remain unclear. In order to correlate clinical presentation, pathological assessment, and treatment with outcome, we have analyzed our institution's recent experience with these tumors. METHODS: Records of adult patients admitted to our institution between July 1982 and December 1991 were reviewed. RESULTS: During this period, 38 adult patients (> 16 years of age) were admitted to our institution with a primary gastrointestinal sarcoma. They accounted for 2% of all adult sarcoma admissions during that period. The study population was composed of 26 men and 12 women. Ages ranged from 29 to 82 years (mean 59). Disease was localized to the primary site in 30 patients (81%). The stomach was the most frequent site of disease (20 cases). The small bowel was affected in nine cases (five duodenum, four jejunum) and the large bowel in nine cases (two colon, seven rectum). Ninety-two percent of patients were symptomatic at presentation. A complete resection was performed in 27 cases, incomplete resection in seven cases, and biopsy only in the remaining three patients. Nine patients received doxorubicin-based chemotherapy. Leiomyosarcoma (n = 35) was the predominant histological diagnosis. Twenty-six tumors were classified as high grade (68%) and 12 as low grade (32%). Overall actuarial 5-year survival was 28% (median follow-up 26 months). Weight loss (p = 0.02) and pain at presentation (p = 0.05) were adverse prognostic factors. Histological grade (p = 0.0002), completeness/extent of surgical resection (p = 0.005), or small bowel primary site were significant determinants of overall survival. The resection of contiguous organs did not affect survival if the primary tumor was completely excised (p = 0.422). Age, race, sex, presentation (prior surgery), tumor size, or adjuvant therapy were not significant prognostic factors. Recurrence was noted in 44% after complete resection, and mean time to recurrence was 9 months (median 7, range < 1-37). Hepatic metastases (42%) and local recurrence (42%) were the predominant sites of initial failure. For patients with a complete resection, grade was the major prognostic determinant (5-year survival: high grade/complete resection 18% vs. low grade/complete resection 72%, p = 0.002). CONCLUSION: The prognosis of gastrointestinal sarcomas is poor. Complete surgical excision is the optimal therapy. However, our results suggest that surgery alone is inadequate for high-grade tumors. We believe that these patients should be considered candidates for investigational adjuvant therapies.

This article has been cited by other articles:

				R. H. I. Andtbacka, C. S. Ng, C. L. Scaife, J. N. Cormier, K. K. Hunt, P. W. T. Pisters, R. E. Pollock, R. S. Benjamin, M. A. Burgess, L. L. Chen, et al. Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib Ann. Surg. Oncol., January 1, 2007; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]

				K. Sandrasegaran, A. Rajesh, J. Rydberg, D. A. Rushing, F. M. Akisik, and J. D. Henley Gastrointestinal Stromal Tumors: Clinical, Radiologic, and Pathologic Features Am. J. Roentgenol., March 1, 2005; 184(3): 803 - 811. [Full Text] [PDF]

				J. N. Cormier and R. E. Pollock Soft Tissue Sarcomas CA Cancer J Clin, March 1, 2004; 54(2): 94 - 109. [Abstract] [Full Text] [PDF]

				H. Medina-Franco, A. Ramos-De la Medina, R. Cortes-Gonzalez, J. Baquera, A. Angeles-Angeles, M. M. Urist, I. E. Eltoum, and M. J. Heslin Expression of p53 and Proliferation Index as Prognostic Factors in Gastrointestinal Sarcomas Ann. Surg. Oncol., March 1, 2003; 10(2): 190 - 195. [Abstract] [Full Text] [PDF]

				G. J. C. Burkill, M. Badran, O. Al-Muderis, J. Meirion Thomas, I. R. Judson, C. Fisher, and E. C. Moskovic Malignant Gastrointestinal Stromal Tumor: Distribution, Imaging Features, and Pattern of Metastatic Spread Radiology, February 1, 2003; 226(2): 527 - 532. [Abstract] [Full Text] [PDF]

				R. Dagher, M. Cohen, G. Williams, M. Rothmann, J. Gobburu, G. Robbie, A. Rahman, G. Chen, A. Staten, D. Griebel, et al. Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors Clin. Cancer Res., October 1, 2002; 8(10): 3034 - 3038. [Abstract] [Full Text] [PDF]

				M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid Oncologist, October 1, 2002; 7(5): 393 - 400. [Abstract] [Full Text] [PDF]

				C. Menon, S. N. Kutney, S. C. Lehr, S. K. Hendren, T. M. Busch, S. M. Hahn, and D. L. Fraker Vascularity and Uptake of Photosensitizer in Small Human Tumor Nodules: Implications for Intraperitoneal Photodynamic Therapy Clin. Cancer Res., December 1, 2001; 7(12): 3904 - 3911. [Abstract] [Full Text] [PDF]

				J. R. Howe, L. H. Karnell, and C. Scott-Conner Small Bowel Sarcoma: Analysis of Survival From the National Cancer Data Base Ann. Surg. Oncol., July 1, 2001; 8(6): 496 - 508. [Abstract] [Full Text] [PDF]

				J. A. Crosby, C. N. Catton, A. Davis, J. Couture, B. O'Sullivan, R. Kandel, and C. J. Swallow Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database Ann. Surg. Oncol., January 1, 2001; 8(1): 50 - 59. [Abstract] [Full Text] [PDF]